

Dermal Allograft Innovation Grants

MTF Biologics is pleased to announce the opening of the **2026 Dermal Allografts Innovations Research Grants**, a new funding opportunity focused on advancing next-generation of technologies in allograft dermis and skin.

Allograft dermal matrices (ADMs) and skin allografts are widely used in reconstructive and regenerative procedures, including **breast surgery, wound healing, and abdominal wall reconstruction**. Current applications primarily rely on sheet-based products. However, there is an increasing need for **innovative technologies** that expand the versatility of ADM and skin, increase clinical utility, improve storage and handling, and enable **new clinical applications**. Emerging concepts such as **flowable or particulate ADM, 3D-printed constructs, tissue-engineered skin, viable dermal tissues, and advanced preservation technologies** represent transformative opportunities for patient care.

MTF Biologics invites **Translational Research** proposals that accelerate innovation in allograft dermis and skin by developing **new enabling technologies, novel clinical uses, advanced processing or delivery methods, and next-generation product forms**.

Program Objectives

The Dermal Allograft Innovations Grant aims to support research that will:

- Drive **technological breakthroughs** in allograft dermis and skin beyond traditional sheet-based formats.
- Develop **new tissue products** (e.g., flowable ADM, ground or particulate ADM, viable dermal tissue constructs) to improve adaptability and efficacy in complex surgical scenarios.
- Explore **integration with advanced platforms**, including 3D bioprinting and tissue engineering approaches for skin regeneration.
- Innovate **processing and preservation technologies**, such as room-temperature storage solutions for burn-care grafts that reduce the need for cryopreservation.
- Advance ADM applications in existing clinical indications through **novel designs and transformative product concepts**.

Examples of Eligible Research Areas

- Creation of **novel dermal or skin allograft forms** (flowable, injectable, hybrid, or modular constructs).

A NON-PROFIT ORGANIZATION
Equal Opportunity Employer

- Development of **advanced dermis or skin compositions**, including 3D-printing-compatible biomaterials, tissue-engineered skin substitutes, or viable allograft tissues.
- Advancement of **processing technologies** to improve shelf life, sterility, preservation, transportability, or clinical usability.
- Translational studies demonstrating **clinical feasibility, performance improvements, or expanded clinical applications**.

Other relevant research topics aligned with the program objectives will be considered.

Exclusions

- Projects focused solely on **incremental improvements** to existing ADM sheet formats without meaningful technological innovation.
- Projects in which the enabling technology is **not allograft-based**.

Funding and Eligibility

- Funding available: **Up to \$100,000 for a 12-month project period.**
- **Up to two additional 12-month cycles** of continued funding may be awarded based on progress, milestones achieved, and programmatic impact.
- Eligible applicants include investigators with expertise in **tissue engineering, regenerative medicine, biomaterials science, plastic and reconstructive surgery**, or related fields, who hold an appointment at an **academic institution, teaching hospital, or research organization**.

Letters of Intent (LOI) Due Date - March 23, 2026

Announcement of LOI positive review and Request for full proposal – by end of April 2026

Full Proposal Due Date (if LOI is approved) - June 15, 2026

Announcement of Awards to Grant Recipients – by end of October 2026

Please visit <https://proposalcentral.com/> and search for MTF Biologics for application forms and instructions.

A NON-PROFIT ORGANIZATION
Equal Opportunity Employer

TOLL-FREE 800-946-9008 | MAIN 732-661-0202